AU2009234338B2 - Methods and compositions related to internalizing RGD peptides - Google Patents

Methods and compositions related to internalizing RGD peptides Download PDF

Info

Publication number
AU2009234338B2
AU2009234338B2 AU2009234338A AU2009234338A AU2009234338B2 AU 2009234338 B2 AU2009234338 B2 AU 2009234338B2 AU 2009234338 A AU2009234338 A AU 2009234338A AU 2009234338 A AU2009234338 A AU 2009234338A AU 2009234338 B2 AU2009234338 B2 AU 2009234338B2
Authority
AU
Australia
Prior art keywords
seq
tumor
amino acid
peptide
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009234338A
Other languages
English (en)
Other versions
AU2009234338A1 (en
AU2009234338A2 (en
Inventor
Erkki Ruoslahti
Kazuki Sugahara
Tambet Teesalu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Burnham Institute For Medical Res
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Institute For Medical Res, Sanford Burnham Prebys Medical Discovery Institute filed Critical Burnham Institute For Medical Res
Publication of AU2009234338A1 publication Critical patent/AU2009234338A1/en
Publication of AU2009234338A2 publication Critical patent/AU2009234338A2/en
Application granted granted Critical
Publication of AU2009234338B2 publication Critical patent/AU2009234338B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
AU2009234338A 2008-01-18 2009-01-16 Methods and compositions related to internalizing RGD peptides Active AU2009234338B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2213108P 2008-01-18 2008-01-18
US61/022,131 2008-01-18
PCT/US2009/031305 WO2009126349A2 (en) 2008-01-18 2009-01-16 Methods and compositions related to internalizing rgd peptides

Publications (3)

Publication Number Publication Date
AU2009234338A1 AU2009234338A1 (en) 2009-10-15
AU2009234338A2 AU2009234338A2 (en) 2010-08-05
AU2009234338B2 true AU2009234338B2 (en) 2014-07-24

Family

ID=41117566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009234338A Active AU2009234338B2 (en) 2008-01-18 2009-01-16 Methods and compositions related to internalizing RGD peptides

Country Status (8)

Country Link
US (2) US8367621B2 (https=)
EP (1) EP2242764B1 (https=)
JP (3) JP5985152B2 (https=)
CN (1) CN101951938B (https=)
AU (1) AU2009234338B2 (https=)
BR (1) BRPI0906739A2 (https=)
CA (1) CA2710554A1 (https=)
WO (1) WO2009126349A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514160A (ja) 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物
US8263133B2 (en) * 2009-02-18 2012-09-11 The Regents Of The University Of California Multivalent clustering targeting strategy for drug carriers
WO2011005540A1 (en) * 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
WO2011127405A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
WO2012040105A2 (en) * 2010-09-21 2012-03-29 Kansas State University Research Foundation Renilla/gaussia transfected cells as a light source for in-situ photodynamic therapy of cancer
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
BR112014030716A2 (pt) * 2012-06-07 2018-06-26 Dcb Usa Llc fragmentos de fibronectina modificada ou variantes e usos dos mesmos
USD730496S1 (en) 2012-11-06 2015-05-26 Michael Schulze Plumbing pipe
WO2014085297A1 (en) * 2012-11-27 2014-06-05 Colorado State University Research Foundation Multifunctional bacteriophage for delivery of therapeutic agents and imaging reagents
USD729910S1 (en) 2013-05-15 2015-05-19 MPS Technologies, LLC Plumbing pipe
US9975933B2 (en) * 2013-05-23 2018-05-22 Ajou University Industry-Academic Cooperation Foundation Tumor tissue-penetrating peptide specific to neuropilin and fusion protein having same peptide fused therein
CN104774246B (zh) * 2014-03-21 2018-05-04 中山大学附属肿瘤医院 Nrp-1特异性肿瘤靶向多肽及其应用
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016205027A1 (en) * 2015-06-15 2016-12-22 Oklahoma Medical Research Foundation Ubiquitin interacting motif peptides as therapeutics
EP3124052A1 (de) * 2015-07-30 2017-02-01 Albrecht Piiper Verfahren zur diagnose von karzinomen mittels irgd und magnetresonanztomographie (mrt)
RU2599462C1 (ru) * 2015-09-22 2016-10-10 Общество с ограниченной ответственностью "БИОТЕХНОЛОГИЯ" (ООО "БИОТЕХНОЛОГИЯ") Способ полисигнальной активации апоптоза клеток злокачественных солидных опухолей
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
KR101926918B1 (ko) 2016-08-30 2018-12-07 한양대학교 산학협력단 항암 활성을 갖는 펩티드, 이를 유효성분으로 함유하는 암 예방 및 치료용 약학 조성물 및 건강기능식품 조성물
EP3354270A4 (en) * 2016-10-21 2019-04-24 Obshestvo S Ogranichennoi Otvetstvennost'yu "Biotehnologiya" METHOD FOR ACTIVATION OF APOPTOSIS OF CELLS WITH MULTIPLE SIGNALING OF SOLID MALIGNANT TUMORS
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3628047A1 (en) * 2017-05-02 2020-04-01 Sanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
CN108484733B (zh) * 2018-03-01 2021-06-25 国家纳米科学中心 双亲性靶向穿膜肽及其自组装的纳米探针、载药纳米颗粒
CN108676097B (zh) * 2018-05-24 2020-01-14 北京肽和生物科技有限公司 一种靶向肿瘤细胞的嵌合肽或嵌合蛋白及其应用
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
US12351653B1 (en) 2019-03-08 2025-07-08 Lisata Therapeutics, Inc. Pharmaceutical compositions comprising novel cyclic peptides
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2021207742A1 (en) 2020-04-10 2021-10-14 Mi2 Holdings LLC Nanoparticles for use in photodynamic therapies and methods of making, evaluating and using the same
CN111690071A (zh) * 2020-07-01 2020-09-22 中国药科大学 一种具有靶向穿膜性的抗肿瘤多肽
CN116615237A (zh) * 2020-12-01 2023-08-18 纽约市哥伦比亚大学理事会 使用免疫调节剂使癌症对免疫疗法敏感的方法
KR20240018458A (ko) * 2021-05-04 2024-02-13 센드 테라퓨틱스 인코포레이티드 iRGD-유사체 및 관련된 치료 방법
US20220378711A1 (en) * 2021-05-11 2022-12-01 United States Government As Represented By The Department Of Veterans Affairs PH-Responsive Nanoparticles for Treating Cancer
CN115466311A (zh) * 2021-06-10 2022-12-13 首都医科大学 抗粘附迁移和侵袭的18β-甘草次酸-RGDK,其合成,抗癌转移活性和应用
CN115869312B (zh) * 2022-12-27 2024-02-27 哈尔滨吉象隆生物技术有限公司 一种pdc抗肿瘤药物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075540A1 (en) * 2008-12-23 2010-07-01 Burnham Institute For Medical Research Methods and compositions for synaphically-targeted treatment for cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465427B1 (en) * 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
EP1326980B1 (en) * 2000-10-16 2008-03-19 Genentech, Inc. Methods of treatment using wisp polypeptides
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
ATE552860T1 (de) * 2003-01-31 2012-04-15 Celldex Res Corp Antikörper-vakzine-konjugate und ihre verwendungen
US20080207502A1 (en) * 2004-10-14 2008-08-28 Sopherion Therapeutics, Inc. Anti-Angiogenic Peptides and Methods of Use Thereof
US20070299043A1 (en) * 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
JP2011514160A (ja) * 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075540A1 (en) * 2008-12-23 2010-07-01 Burnham Institute For Medical Research Methods and compositions for synaphically-targeted treatment for cancer

Also Published As

Publication number Publication date
US20090246133A1 (en) 2009-10-01
US9115170B2 (en) 2015-08-25
JP2016121182A (ja) 2016-07-07
JP5985152B2 (ja) 2016-09-06
EP2242764A4 (en) 2011-06-08
BRPI0906739A2 (pt) 2015-08-04
AU2009234338A1 (en) 2009-10-15
CN101951938B (zh) 2016-04-13
EP2242764B1 (en) 2016-03-30
JP2014028862A (ja) 2014-02-13
CN101951938A (zh) 2011-01-19
WO2009126349A3 (en) 2010-05-14
AU2009234338A2 (en) 2010-08-05
EP2242764A2 (en) 2010-10-27
US20130343989A1 (en) 2013-12-26
WO2009126349A2 (en) 2009-10-15
US8367621B2 (en) 2013-02-05
CA2710554A1 (en) 2009-10-15
JP2011510019A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
AU2009234338B2 (en) Methods and compositions related to internalizing RGD peptides
US8753604B2 (en) Methods and compositions for synaphically-targeted treatment for cancer
Alberici et al. De novo design of a tumor-penetrating peptide
Mousavizadeh et al. Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: a systematic review
Teesalu et al. Tumor-penetrating peptides
Yao et al. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method
CA3032186C (en) Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
CA2843470C (en) Brain tumor targeting peptides and methods
Lingasamy et al. Homing peptides for cancer therapy
Soudy et al. Engineered peptides for applications in cancer-targeted drug delivery and tumor detection
EP2949658A2 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
JP6223132B2 (ja) 腫瘍および損傷のターゲティングに関する方法および組成物
Enyedi et al. Development of cyclic NGR peptides with thioether linkage: structure and dynamics determining deamidation and bioactivity
WO2012045719A2 (en) New vascular targeting peptides
Lempens et al. Dendrimer display of tumor-homing peptides
CN111511917B (zh) 肽结合物
AU2021412432B2 (en) Chlorotoxin derivatives and use thereof
US20240000967A1 (en) Use of multi-specific human albumin nanoparticles decorated with antibody fragments and loaded with cytotoxics
US20260034193A1 (en) Brevican-Binding Peptides for Brain Tumor Imaging
Hunt Tumor homing peptides for drug delivery and imaging.
Cupka Development of an αᵥβ₆-Binding Peptide for In Vivo Applications: Modulation of Serum Stability and Biodistribution
Ahmed Design, Synthesis and Evaluation of Cancer Targeting α-Peptides and Novel Peptidomimetic β-Peptides

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 JUL 2010

FGA Letters patent sealed or granted (standard patent)